| Inclusion Criteria: | Age greater than or equal to 30
No prior history of ovarian cancer, including low malignant potential cancers (LMP) or primary papillary serous carcinoma of the peritoneum.
Ovary status: (a) To be eligible for the RRSO arm of this study, subjects must have at least one intact ovary- (b) To be eligible for the screening arm of this study which targets primary ovarian cancer as the endpoint, subjects must have at least one intact ovary- (c) To be eligible for the screning arm of this study which targets primary peritoneal cancer as the endpoint, both ovaris and fallopian tubes must have been removed (women w/removal of ovaries while on GOG-0199).
Women who have not had both ovaries removed prior to study entry.
The family contains at least two ovarian and/or breast cancers among the subject or first or second degree relatives of the subject within the same lineage. This condition is satisfied by multiple primary cancers in the same person. Where breast cancer is required to meet this criterion, at least one breast cancer must be diagnosed prior to menopause (age at diagnosis less than or equal to 50 if age at menopause is unknown)
The subject is of Ashkenzai Jewish ethnicity with one first degree or two second degree relatives with breast and/or ovarian cancer. Where breast cancer is required to meet this criterion, at least one case must have been diagnosed prior to menopause (or at age less than or equal to 50 if age at menopause is unknown)
The subject is of Ashkenazi ancestry and has had breast cancer herself. To meet this criterion, her breast cancer must have been diagnosed prior to menopause (age at diagnosis less than or equal to 50 if age at menopause is unknown)
The family of the subject has a documented deleterious BRCA1 or BRCA2 mutation - either: the subject herself has tested positive for a deleterious BRCA1 or BRCA2 mutation- or the subject has a first- or second-degree relative with a deleterious BRCA1 or BRCA2 mutation.
Probability of carrying a BRCA1/2 mutation given fam pedigree of breast and OC's exceed 20% calc by BRCAPRO. Note:BRCAPRO does NOT need to be calc on everyone. Pt elig based on fam hx which meets 1 of specific patterns desc regardless of BRCAPRO result. BRCAPRO is valuable in fam where genetic testing hasnt been done and fam hx doesnt fit 1 of specific patterns desc but patterns of ca indicate fam might still be consid high-risk. Then if BRCAPRO est of being a mutation carrier is >20%
pt IS elig
Signed an approved informed consent and authorization permitting release of personal health information. |